3-V Biosciences

3-V Biosciences is a privately held biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. 3-V Biosciences was founded by The Column Group (TCG) and Kleiner Perkins Caulfield & Byers (KPCB) in March 2007. In April 2007, the original laboratory was opened in Zürich, Switzerland in close proximity to the company’s founders at the ETH (Swiss Federal Institute of Technology) and the University of Zürich. Host pathway screening began in November 2007 and continues today.
Company Growth (employees)
Type
Private
HQ
Menlo Park, US
Founded
2007
Size (employees)
16 (est)
3-V Biosciences was founded in 2007 and is headquartered in Menlo Park, US

Key People at 3-V Biosciences

Merdad Parsey

Merdad Parsey

Chief Executive Officer & BOD
Sara Nayeem

Sara Nayeem

Investor
George Kemble

George Kemble

Chief Scientific Officer
Stephen R. Brady

Stephen R. Brady

Chief Business Officer
Richard Klausner

Richard Klausner

Former Director
Douglas I Buckley,

Douglas I Buckley,

Vice President, Biology

3-V Biosciences Office Locations

3-V Biosciences has office in Menlo Park
Menlo Park, US

3-V Biosciences Metrics

3-V Biosciences Summary

Founding Date

2007

Total Funding

$128.9 m

Latest funding size

$14.3 m

Time since last funding

about 2 years

Investors

We estimate that 3-V Biosciences's latest funding round in March 2015 was $14.3 m. In total, 3-V Biosciences has raised $128.9 m
We estimate that 3-V Biosciences's current employees are approximately 10% female and 90% male.

3-V Biosciences Company Life

You may also be interested in